Proteome narrows loss in full-year 2007
UK-based applied proteomics specialist Proteome Sciences has narrowed its loss in the calender year ending December 31, 2007, on a near fourfold increase in revenue.
The firm posted turnover of L265,593 ($520,403), 388% up on the year before when the firm recorded just L68,469. This left the company with a net loss of L5.3 million, or 3.99 pence per share, versus L5.6 million, or 4.29 pence per share, year-on-year.
In April, 2008, Proteome entered into a global exclusive license agreement for its TMT (isobaric tandem mass tag technology), which is patented throughout the USA and Europe, with Thermo Fisher Scientific.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze